aiming to improve survival in cancer.
February 6, 2023: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital
February 3, 2023: MaaT Pharma Receives U.S. FDA Response Outlining Path Forward for Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease and Reports Cash and Revenues for Fourth Quarter 2022
Like what you see?
Join the MaaT Pharma adventure!
Bring your talents, your passion and join an inclusive, creative, and multidisciplinary team. We aim to leverage the potential of microbiome to improve the treatment of patients with cancer.
Learn more about our values, our environment and see what we have to offer to you!